Neurogen Announces Aplindore Preclinical Data to Be Presented at Neuroscience 2007

Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, today announced that data from a preclinical study with aplindore, the Company’s compound for the treatment of Parkinson’s disease and restless legs syndrome (RLS), will be presented on November 6 in a poster at Neuroscience 2007, the Society for Neuroscience annual meeting in San Diego, California. The poster, "Aplindore, a novel potent dopamine D2 receptor partial agonist is efficacious as a monotherapy or when combined with L-DOPA in treating motor disabilities in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-treated marmoset, a non-human model of Parkinson's Disease,” will be displayed at the San Diego Convention Center in Exhibit Halls B-H during the "Parkinson’s Disease: Dyskinesias” session on Tuesday, November 6, from 4:00-5:00 p.m. PT (Poster Board Number: N14). The number of patients diagnosed with Parkinson’s disease and RLS continues to grow and Neurogen believes there is need for improvement in side effect profiles and dosing regimen that may be made possible by aplindore. Dopamine agonists currently available for the treatment of Parkinson’s disease and RLS are full agonists at D2 receptors and have many significant side effects. In addition they require a long titration period--up to seven weeks in Parkinson’s disease and four to seven weeks in RLS. The currently available D2 full agonist treatments for Parkinson’s disease produce side effects in many patients that include daytime somnolence or drowsiness, dyskinesias (sudden episodes of abnormal involuntary movements), and hallucinations. While these drugs have also proved effective in the treatment of RLS, many patients still suffer side effects of augmentation (a worsening of symptoms), nausea, constipation, and hypotension. By avoiding over-stimulation of healthy parts of the brain that is seen with the currently marketed D2 full agonists, Neurogen believes aplindore’s partial agonist profile may provide an improved side-effect profile and shorter dosing titration period in Parkinson’s disease and RLS. The Company expects to commence Phase 2 trials in Parkinson’s disease and Restless Legs Syndrome (RLS) following the manufacture of clinical supplies of aplindore. About Neurogen Neurogen Corporation is a drug discovery and development company focusing on small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including insomnia, obesity, pain, Parkinson’s disease, restless legs syndrome (RLS), and depression. Neurogen conducts its research and development independently and, when advantageous, collaborates with world-class pharmaceutical companies to access additional resources and expertise. Neurogen Safe Harbor Statement The information in this press release contains certain forward-looking statements, made pursuant to applicable securities laws, which involve risks and uncertainties as detailed from time to time in Neurogen's SEC filings, including its most recent 10-K. Such forward-looking statements relate to activities, events or developments that Neurogen believes, expects or anticipates will occur in the future and include, but are not limited to, earnings estimates, statements that are not historical facts relating to Neurogen’s future financial performance, its growth and business expansion, its financing plans, the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. These statements are based on certain assumptions made by Neurogen based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of Neurogen's drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of Neurogen's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, Neurogen’s ability to retain key employees, sufficiency of cash to fund Neurogen's planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. Although Neurogen believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Forward-looking statements represent the judgment of Neurogen’s management as of the date of this release and Neurogen disclaims any intent and does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required under applicable law.